65,437 trials
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Week 26) — -1.1; -1.7; -1.7; -1.4 Percentage point of HbA1c — p=<0.0001
Esophagogastroduodensocopy (EGD) Procedure
Primary: Intracuff Pressures During Probe Insertion — 22; 34; 41; 37 cmH2O
HIV-1 Infection
Primary: Number of Participants Who Met the Study-defined Composite Safety Endpoint — 3 Participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Number of Treatment-emergent Adverse Events (TEAEs) — 330; 350; 324; 178 Events
Opioid-Induced Bowel Dysfunction
Primary: Mean Weekly Spontaneous Bowel Movements (SBMs) Per Month — 1.4; 4.9; 4.9; 5.0 Weekly SBMs
Metastatic Breast Cancer
Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983
Healthy
Primary: Feasibility of Esophageal Imaging in Subjects Who Successfully Swallow the OCT Capsule in the Primary Care Setting. — 45 Participants
Atrial Fibrillation
Primary: Number of Participants Experiencing Significant Hypotension — 2 Participants
Lymphoma, Follicular
Primary: Percentage of Participants Achieving Complete Response (CR) at End of Induction (EOI), as Determined by the Independent Review Committee (IRC) Using Modified Lugano 2014…
Peripheral Neuropathy
Primary: The Incidence of System and/or Procedure Related Serious Adverse Events (SAEs). — 1 Participants
Schizophrenia
Primary: Percentage of Participants With Adverse Events — 156; 79; 95; 38 Participants
Neoplasm
Primary: Proportion of Patients With a Reportable Genetic Variant — 0.61 proportion of participants
Suicide, Attempted
Primary: Suicidal Ideation Intensity as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS) Intensity Subscale. — 13.0; 2.50; 2.60 score on a scale
Depressive Disorder, Major
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study — -4.9; -4.8; -5.4 Score on a Scale — p=0.8862
Infection · Bacteremia
Primary: Patient Clinical Response to Telavancin — 32 Participants